Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30173749 | 1.00 | NPFFR2 (0.47) | NPFFR2KDRPDK1KMOSLC6A3 | |
| SCHEMBL23792959 | 0.87 | NPFFR2 (0.47) | NPFFR2KDRPDK1KMOSLC6A3 | |
| SCHEMBL20702651 | 0.83 | NPFFR2 (0.50) | NPFFR2KDRPDK1SLC6A3 | |
| SCHEMBL30991460 | 0.83 | NPFFR2 (0.50) | NPFFR2KDRPDK1SLC6A3 | |
| SCHEMBL20702662 | 0.81 | KDR (0.50) | NPFFR2KDRPDK1SLC6A3PPARG | |
| SCHEMBL4109066 | 0.80 | KMO (0.65) | KMOSLC6A3 | |
| SCHEMBL1726226 | 0.80 | GSK3B (0.54) | NPFFR2KDRPDK1SLC6A3PPARG | |
| SCHEMBL30298640 | 0.80 | GSK3B (0.54) | NPFFR2KDRPDK1SLC6A3PPARG | |
| SCHEMBL18120301 | 0.80 | NPFFR2 (0.50) | NPFFR2KDRPDK1SLC6A3KDM4E | |
| SCHEMBL20702566 | 0.78 | KDR (0.51) | NPFFR2KDRPDK1SLC6A3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12157731-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2024-12-03 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-4114529-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220356178-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2022-11-10 | — | — | US | disclosed |
| WO-2021178488-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021178488-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| US-9969677-B2 | Histone acetyltransferase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170121276-A1 | HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-05-04 | — | — | US | disclosed |
| US-20090221645-A1 | Dihydroimidazothiazole Derivatives | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221645-A1 | Dihydroimidazothiazole Derivatives | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221645-A1 | Dihydroimidazothiazole Derivatives | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-1851232-A2 | DIHYDROIMIDAZOTHIAZOLE DERIVATIVES | Prosidion Limited (GB) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006085118-A2 | DIHYDROIMIDAZOTHIAZOLE DERIVATIVES | PROSIDION LIMITED (GB) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | NPFFR2 2737/4885KDR 3870/4885PDK1 538/4885 |
| US-20090221645-A1 | Dihydroimidazothiazole Derivatives | TPH1, HTR3B, HTR1A | NPFFR2 291/4885KDR 1794/4885PDK1 2895/4885 |
| US-12157731-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | NPFFR2 2737/4885KDR 3870/4885PDK1 538/4885 |
| US-20170121276-A1 | HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF | EP300, KAT2A, HTT | NPFFR2 4189/4885KDR 4841/4885PDK1 2814/4885 |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | NPFFR2 2737/4885KDR 3870/4885PDK1 538/4885 |
| US-20220356178-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | NPFFR2 2737/4885KDR 3870/4885PDK1 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.